Background:
Triple-negative BC is the most aggressive type of breast cancer and its lack of
responsiveness to conventional therapies requires screening of new chemical entities. Anti-migratory compounds
are promising to treat metastatic cancer since they inhibit one of the main steps of the metastatic cascade.
Spirocyclic compounds are non-conventional structures used as building blocks for the synthesis of biologically
active molecules and considered interesting structures in the search for new targets in cancer research.
Objective:
Here we evaluated the potential of eight synthetic spirocyclohexadienones as cell migration inhibitors.
Methods:
The anti-migratory ability of compounds was tested by wound healing and Boyden chamber
approaches. Experiments in tubulin were performed by fluorescence and tubulin polymerization techniques.
Finally, compounds were submitted to cell proliferation inhibition and flow cytometry assays to explore the
mechanism by which they inhibit cell migration.
Results:
Four compounds inhibited cell migration significantly. Analogs containing the 3,4,5-trimethoxyphenil
ring at R1 position were the most potent and, thus, selected for additional experiments. Tubulin polymerization
and fluorescence assays highlighted a possible binding of spirocyclohexadienones in the colchicine binding site;
however, these compounds did not affect the cell cycle to the same extent as colchicine. Cell proliferation was
affected and, notably, the most potent analogs induced apoptosis of tumor cells, suggesting a different
mechanism by which they inhibit cell migration.
Conclusion:
We presented, for the first time, a series of eight synthetic spirocyclohexadienones with the ability
to inhibit TNBC cell migration. These compounds represent a new category to be explored as anticancer agents.
</jats:sec